| 1-R56-EB030512-01A1 |
Cerenkov 2.0 – Cerenkov-activated agents for imaging and therapy |
Jan Grimm |
Sloan-Kettering Inst Can Research |
| 5-R01-EB025197-02 |
Characterization and Quantification of Myelin in the Central Nervous System |
Yanming Wang |
Case Western Reserve University |
| 5-R01-EB029259-04 |
Chelation strategies for s-, p-, and f-block radionuclides for targeted alpha therapy |
Justin Wilson |
Cornell University |
| 2-R56-EB029259-05 |
Chelators to Enable Theranostic Alpha Particle Radiotherapeutic Agents |
Justin Wilson |
Cornell University |
| 5-R21-EB028425-03 |
Chemical tools to decode nuclear lamina-ome |
Bingbing Li |
Oregon Health & Science University |
| 5-R21-EB030071-04 |
Cherenkov luminescence mediated excitation of discrete lanthanide optical probes |
Eszter Boros |
University of Wisconsin-Madison |
| 5-R01-EB021155-08 |
Copper-mediated Radiofluorination: from Proof-of-Concept to Clinical Impact |
Peter Scott |
University of Michigan at Ann Arbor |
| 5-F31-EB034165-02 |
CT imaging and therapy of inflammatory bowel disease via catalytic ceria nanoparticles |
Derick Rosario |
University of Pennsylvania |
| 1-R15-EB029559-01 |
Designing Intelligent Iron-Based MRI Contrast Agents |
Joshua Sokoloski |
Salisbury University |
| 5-R01-EB029429-04 |
Developing a pretargeting strategy to detect Fe(II) for nuclear medicine applications |
Michael Evans |
University of California, San Francisco |
